Sunifiram: The Definitive Guide

What is Sunifiram?

Sunifiram, also called DM-235, is a synthetic piperazine derivative developed during medicinal-chemistry work on cognition-related compounds. It has no nutritional role, food source, deficiency state, recommended intake or established upper intake level. It is often sold beside racetams, but its structure does not make it a conventional dietary nutrient or an approved cognition medicine. [1], [5]

The evidence gap is decisive. A current ClinicalTrials.gov search returned no Sunifiram study, and the verified literature used in this guide contains no human efficacy trial, human pharmacokinetic study or systematic human safety evaluation. Claims about focus, memory, onset, duration or “optimal” milligram amounts therefore cannot be tied to a human clinical program. [8]

Sunifiram did alter memory-related tasks in mice and rats after experimentally induced impairment. It also changed long-term potentiation and signaling proteins in isolated mouse hippocampal tissue. Those studies can generate hypotheses. They cannot show that an online capsule improves memory in a healthy person or establish how the human body absorbs, metabolizes or clears the compound. [2], [6], [7]

Typical Sunifiram Research Protocols

The repeated low numbers are easy to misuse. Milligrams per kilogram in a rodent, nanomolar concentration in a tissue bath and milligrams in a human capsule are different quantities. This guide performs no body-surface-area conversion because such arithmetic cannot supply missing human absorption, exposure, target engagement or toxicity data.

Model

Record species, impairment method, behavioral task or isolated tissue; do not label a rodent model as human Alzheimer’s disease.

Exposure

Keep route, amount per administration, timing and duration in the source’s original units.

Evidence boundary

Record that no human pharmacokinetic, efficacy or safety protocol was identified.

What is Sunifiram commonly used for?

Memory and cognitive-enhancement claims

Online sellers and forums commonly frame Sunifiram as a memory or focus compound. The directly verified evidence does not test that proposition in people. The 2002 study tested whether DM-235 prevented amnesia induced by scopolamine, mecamylamine, baclofen or clonidine in mice and scopolamine-associated water-maze impairment in rats. This is not the same question as improving everyday memory in a healthy adult. [2]

The review literature sometimes calls Sunifiram far more potent than piracetam by weight in those preclinical tasks. Potency within a particular animal model does not mean greater human benefit, a lower safe human dose or a better risk–benefit balance. No human head-to-head comparison exists. [2], [4]

Olfactory-bulbectomy model

Moriguchi and colleagues removed the olfactory bulbs of mice, waited ten days and then administered oral Sunifiram once daily for 7–12 days. Spatial-reference and object-recognition measures and hippocampal LTP improved. Depressive behavior did not. This is a surgically altered mouse model, not a clinical Alzheimer’s trial, and the mixed outcome should remain visible. [7]

What does the proposed mechanism show?

In mouse hippocampal slices, 10–100 nM Sunifiram enhanced NMDA-receptor-dependent long-term potentiation in a bell-shaped relationship that peaked at 10 nM. A glycine-site antagonist and a Src-family inhibitor blocked parts of the response, and the experiment measured changes in PKCα, CaMKII and receptor phosphorylation. [6]

Earlier work reported increased acetylcholine release from rat cortex and indirect involvement of AMPA signaling without affinity in surveyed receptor-binding assays. The reasonable conclusion is a preclinical signaling hypothesis. “Ampakine” is too simple if it implies demonstrated direct AMPA positive allosteric modulation or proven human cognition. [1], [4]

How do forms and labels differ?

Names include Sunifiram, DM-235 and 1-benzoyl-4-propanoylpiperazine. Unifiram, sapunifiram and Sunifiram-carbamate hybrids are different compounds; structure–activity studies do not make those analogues interchangeable. [3] A bulk powder, capsule, analytical standard and research-laboratory preparation are not interchangeable merely because they share a name.

No approved pharmacy label or validated consumer specification was identified. A vendor assay can address a measured sample’s chemistry, but it cannot create human efficacy data, establish safe contaminants or guarantee every batch. “Research use only” also does not mean a product was reviewed for human use.

How should Sunifiram be stored?

There is no validated consumer storage or shelf-life standard. Keep any unidentified research chemical away from food, medicines, children and pets, and do not transfer it to an unlabeled container. Discarding an unverified product is safer than attempting to authenticate or repackage it at home. Storage cannot correct substitution, contamination or uncertain strength.

What does the human evidence show?

What are the risks and interactions?

The central risk is missing human information. No verified human trial defines common adverse effects, rare harms, seizure risk, cardiovascular effects, psychiatric effects, liver or kidney toxicity, reproductive toxicity, dependence potential or a margin between active and harmful exposure. Absence of reported human harm in a sparse literature is not evidence of safety. [5]

The animal studies were designed to detect memory-related behavior, not to provide comprehensive chronic toxicology. Lack of motor impairment at selected effective amounts in one study cannot exclude organ toxicity, interactions, delayed effects or risk at another exposure. [2]

Because the proposed signaling involves glutamatergic and cholinergic systems, combining Sunifiram with racetams, stimulants, modafinil or adrafinil, antidepressants, antipsychotics, seizure-threshold-altering drugs, sedatives or “choline stacks” is an unstudied experiment. No evidence shows that adding choline prevents headache or makes exposure safer.

Pregnancy, breastfeeding, childhood, older age, seizure history, bipolar or psychotic disorders, cardiovascular disease, kidney or liver disease and perioperative care all increase the need to avoid unsupervised exposure. Seek urgent care for seizure, fainting, chest pain, severe agitation or confusion, new neurologic symptoms, breathing difficulty or suspected poisoning. Contact a poison centre with the container or label available.

What is the legal and anti-doping status?

In the United States, no FDA-approved therapeutic use or ordinary dietary role for Sunifiram was identified. A chemical’s presence in PubChem or an FDA substance-registration system identifies the substance; it does not show approval, supplement eligibility or human-use review. Check the exact product and claim with the relevant regulator rather than treating “research chemical” as a legal category for ingestion. [9]

In Canada, verify any claimed drug in the Drug Product Database and any claimed natural health product in the Licensed Natural Health Products Database. An online listing does not prove a DIN or NPN. [10]

Sunifiram is not named individually in the 2026 WADA list. S0 nevertheless prohibits at all times pharmacological substances that are not addressed elsewhere and have no current approval by a governmental regulatory health authority for human therapeutic use. Athletes should obtain sport-specific advice and avoid assuming that a negative contaminant screen creates permission. [11]

When should use stop?

There is no validated use to continue. Stop exposure to an unverified product and seek clinical or poison-centre advice when symptoms occur or identity is uncertain. Do not try to counteract effects with another nootropic, sedative or stimulant. Emergency symptoms require emergency care.

What should be monitored?

There is no evidence-based wellness monitoring schedule. For clinical assessment after exposure, record product name, vendor, lot, claimed purity, route, amount, time, other medicines or substances, symptom onset and progression. Clinicians decide whether vital signs, neurologic examination, ECG, laboratory tests or observation are appropriate.

A cognitive score recorded after self-exposure cannot separate expectancy, practice effects, sleep, caffeine, product identity and regression to the mean. It should not be used to titrate an experimental compound.

What does community experience add?

Public reports can suggest questions about perceived stimulation, mood, headache, sleep, dose labeling or product sourcing. They cannot confirm chemical identity, establish incidence, recover missing pharmacokinetics or supply a control group. No systematic current community sample was assembled, so this guide reports no consensus dose, sublingual method, onset, duration, cycle, stack or response rate.

How does Sunifiram compare with related compounds?

Common questions

Is Sunifiram a racetam?

It emerged from related cognition-drug research and is often grouped commercially with racetams, but it is a piperazine derivative rather than a conventional pyrrolidone racetam. [1]

Has Sunifiram been tested in people?

No human clinical trial or pharmacokinetic study was identified in the verified literature or current ClinicalTrials.gov search. [8]

What is a safe Sunifiram dose?

No safe human dose is established. The milligram-per-kilogram and nanomolar protocols in this guide are animal and tissue experiments, not starting points for conversion.

Is Sunifiram 1,000 or 10,000 times stronger than piracetam?

Such ratios describe potency in selected animal tasks and vary with the comparison. They do not predict human efficacy, dose equivalence or safety.

Does the mechanism prove memory enhancement?

No. LTP, phosphorylation and neurotransmitter release are mechanistic observations. A meaningful human claim needs controlled clinical outcomes and safety data. [4], [6]

Is sublingual use faster?

No controlled human absorption comparison was identified. Sublingual schedules and onset claims are unverified.

Was a Sunifiram paper retracted?

Yes. A 2022 paper on Sunifiram-carbamate hybrids has a linked 2026 retraction notice. Its results are excluded; the indexed notice does not state a reason, so none is inferred. [12]

Is Sunifiram prohibited in sport?

WADA S0 prohibits non-approved pharmacological substances at all times. Sunifiram is not named individually, but an unnamed substance can still fall within S0. [11]

Glossary

Plain explanations of Sunifiram evidence terms.

Preclinical

Research before adequate human clinical testing, including animal and isolated-tissue experiments.

Passive avoidance

An animal learning task measuring whether an animal avoids a context associated with an aversive event.

Olfactory bulbectomy

Surgical removal of olfactory bulbs in an animal model; it does not reproduce every feature of human disease.

Long-term potentiation

A lasting increase in synaptic signaling studied as one cellular model related to learning.

Bell-shaped response

An effect that rises and then falls across tested concentrations; more exposure does not necessarily create more effect.

Pharmacokinetics

How a body absorbs, distributes, metabolizes and eliminates a substance.

Retraction

Formal removal of a paper from the reliable scientific record.

WADA S0

The category for non-approved pharmacological substances prohibited at all times.

How this guide was researched

Eight PubMed records were fetched directly from NCBI and checked for title, authors, journal, volume, pages, DOI and descendant correction or retraction records. Primary indexed abstracts supplied the animal amounts, routes, timing and outcomes. The full open preclinical review was used for research history and mechanism context. ClinicalTrials.gov was queried directly for Sunifiram and returned no studies. Official WADA, U.S. and Canadian resources supplied regulatory boundaries.

Explore the sources

Related guides

• Piracetam
• Noopept
• Phenylpiracetam
• Modafinil and Adrafinil
• Nootropic compounds

Editorial note

This guide keeps rodent behavior, isolated-tissue mechanism, product identity and human clinical outcomes in separate evidence lanes. It excludes a retracted hybrid-compound paper and does not turn preclinical amounts into a human regimen.